Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOP Trial: Epirubicin in Primary Treatment of Breast Cancer
NCT00162812Phase 2Terminated
- Sponsor
- Institut Jules Bordet
- Start
- Jan 2003
- Primary completion
- Dec 2008
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of epirubicin in breast cancer, sponsored by Institut Jules Bordet. Primary endpoint: Pathologic Complete Response. Started Jan 2003; status: terminated.
02
Drugs
epirubicin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00162812.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00162812.